Metformin is the most widely used plasma glucose-lowering drug for the treatment of type 2 diabetes. It has been shown that metformin increases plasma concentrations of glucagon-like peptide-1 (GLP-1), but it remains unknown whether metformin-induced GLP-1 secretion plays any role for the beneficial effects of metformin on postprandial glucose metabolism. We investigated the effect of metformin-induced GLP-1 secretion during meal ingestion in patients with type 2 diabetes using the GLP-1 receptor antagonist exendin[9-39]. In a double-blinded, double dummy, placebo-controlled, randomized, cross-over study, 15 participants with type 2 diabetes (medians: age 71 years, BMI 30.07 kg/m2, HbA1c 50 mmol/mol) were subjected to 14 days’ metformin and placebo treatment, respectively, in randomized order with at least a 2-week washout period between treatments. At the end of each treatment period, two randomized 4-hour mixed meal tests with either concomitant exendin[9-39] (450 pmol/kg/min) or saline infusion, were carried out. Metformin treatment significantly lowered fasting plasma glucose and postprandial plasma glucose excursions compared to placebo. We observed equal metformin-induced reductions in postprandial plasma glucose excursions during saline and exendin[9-39] infusions. Based on postprandial plasma glucose excursions, using the GLP-1 receptor antagonist exendin[9-39], we cannot confirm that GLP-1 secretion is involved in the beneficial postprandial glucose-lowering effects of metformin in patients with type 2 diabetes.

Disclosure

L.S. Hansen: None. L.S. Gasbjerg: Stock/Shareholder; Self; Antag Therapeutics. A. Brønden: None. N.B. Dalsgaard: None. E. Bahne: None. P.H. Sørensen: None. J.J. Holst: Advisory Panel; Self; Novo Nordisk A/S. Board Member; Self; Zealand Pharma A/S. Speaker's Bureau; Self; Merck Sharp & Dohme Corp., AstraZeneca. Research Support; Self; Danish Diabetes Academy, Novo Nordisk Foundation. Other Relationship; Self; Antag Therapeutics. Other Relationship; Spouse/Partner; Antag Therapeutics. T. Vilsbøll: Advisory Panel; Self; Amgen Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, AstraZeneca, MSD K.K., Sanofi, Novo Nordisk A/S. Consultant; Self; Amgen Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, AstraZeneca, MSD K.K., Sanofi, Novo Nordisk A/S. Speaker's Bureau; Self; Amgen Inc., Boehringer Ingelheim GmbH, Eli Lilly and Company, AstraZeneca, MSD K.K., Sanofi, Novo Nordisk A/S. Research Support; Self; Eli Lilly and Company, Novo Nordisk A/S. F.K. Knop: Advisory Panel; Self; AstraZeneca. Consultant; Self; AstraZeneca. Research Support; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Amgen Inc.. Speaker's Bureau; Self; Merck Sharp & Dohme Corp.. Advisory Panel; Self; Novo Nordisk A/S. Consultant; Self; Novo Nordisk A/S. Speaker's Bureau; Self; Novo Nordisk A/S. Consultant; Self; Amgen Inc.. Advisory Panel; Self; MedImmune, Sanofi. Consultant; Self; Sanofi. Research Support; Self; Sanofi. Speaker's Bureau; Self; Sanofi.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.